These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24092864)

  • 81. SMAD About Hepatitis C Virus Cell Entry and Liver Disease.
    Colpitts CC; Baumert TF
    Gastroenterology; 2017 Jan; 152(1):21-23. PubMed ID: 27889572
    [No Abstract]   [Full Text] [Related]  

  • 82. Clinical development of hepatitis C virus host-targeting agents.
    Zeisel MB; Baumert TF
    Lancet; 2017 Feb; 389(10070):674-675. PubMed ID: 28087068
    [No Abstract]   [Full Text] [Related]  

  • 83. Optimal timing for hepatitis C antiviral therapy in the peritransplant period?
    Cholankeril G; Wong RJ; Kim D; Ahmed A
    Hepatology; 2017 Sep; 66(3):1004. PubMed ID: 28586088
    [No Abstract]   [Full Text] [Related]  

  • 84. If hepatitis C therapy is so great, why isn't everyone doing it?
    Brown RS
    Am J Transplant; 2018 Oct; 18(10):2382-2383. PubMed ID: 29862650
    [No Abstract]   [Full Text] [Related]  

  • 85. Hepatitis C Virus Infection, a New Modifiable Cardiovascular Risk Factor.
    Cacoub P
    Gastroenterology; 2019 Mar; 156(4):862-864. PubMed ID: 30776342
    [No Abstract]   [Full Text] [Related]  

  • 86. Extrahepatic Complications of Hepatitis C Virus Infection in HIV and the Impact of Successful Antiviral Treatment.
    Lo Re V
    Clin Infect Dis; 2017 Feb; 64(4):498-500. PubMed ID: 28172488
    [No Abstract]   [Full Text] [Related]  

  • 87. Beyond viral dependence: The pathological consequences of HCV-induced EGF signaling.
    Roca Suarez AA; Baumert TF; Lupberger J
    J Hepatol; 2018 Sep; 69(3):564-566. PubMed ID: 29937068
    [No Abstract]   [Full Text] [Related]  

  • 88. Reply to: "Real-world data on antiviral treatments for hepatitis C virus infections: Can we define intention to treat or per protocol analyses?".
    Buggisch P; Zeuzem S
    J Hepatol; 2018 Aug; 69(2):553. PubMed ID: 29758332
    [No Abstract]   [Full Text] [Related]  

  • 89. Reply.
    Wang C; Chen G; Lau G
    Clin Gastroenterol Hepatol; 2017 Apr; 15(4):605-606. PubMed ID: 28025157
    [No Abstract]   [Full Text] [Related]  

  • 90. Pharmacies dispensing opioid substitution therapy also play a role in hepatitis C virus elimination.
    Gunn J; Higgs P
    J Am Pharm Assoc (2003); 2018; 58(3):245. PubMed ID: 29551668
    [No Abstract]   [Full Text] [Related]  

  • 91. Hepatitis C: When high drug prices preclude patient benefit.
    Kantarjian HM; Paul S
    Cancer; 2018 Apr; 124(8):1644-1646. PubMed ID: 29486061
    [No Abstract]   [Full Text] [Related]  

  • 92. Optimizing the treatment strategy to achieve hepatitis C virus elimination in Mexico.
    Ruiz I
    Rev Gastroenterol Mex (Engl Ed); 2019; 84(2):267-268. PubMed ID: 31053246
    [No Abstract]   [Full Text] [Related]  

  • 93. Antiviral treatment for hepatitis C: rebalancing cost, affordability, and availability.
    Dusheiko G; Gore C
    Lancet Glob Health; 2019 Sep; 7(9):e1150-e1151. PubMed ID: 31362913
    [No Abstract]   [Full Text] [Related]  

  • 94. Pharmacy-led hepatitis C treatment pathways to help ensure elimination.
    Gunn J; Higgs P
    Lancet Gastroenterol Hepatol; 2019 Jan; 4(1):12-13. PubMed ID: 30527577
    [No Abstract]   [Full Text] [Related]  

  • 95. Multi-omic Analyses Reveal Complex Interactions Between HCV and Hepatocytes Demonstrating That the Red Queen Is Up and Running.
    Gal-Tanamy M
    Gastroenterology; 2019 Aug; 157(2):300-302. PubMed ID: 31255661
    [No Abstract]   [Full Text] [Related]  

  • 96. Reply.
    Fernández Carrillo C; Perelló C; Calleja JL
    Clin Gastroenterol Hepatol; 2017 May; 15(5):791. PubMed ID: 28163213
    [No Abstract]   [Full Text] [Related]  

  • 97. Reply.
    Chhatwal J
    Clin Gastroenterol Hepatol; 2017 Nov; 15(11):1815. PubMed ID: 28782665
    [No Abstract]   [Full Text] [Related]  

  • 98. Elimination of viral hepatitis by 2030: ambitious, but achievable.
    Brierley R
    Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):88-89. PubMed ID: 30647012
    [No Abstract]   [Full Text] [Related]  

  • 99. Can concomitant use of zinc and curcumin with other immunity-boosting nutraceuticals be the arsenal against COVID-19?
    Roy A; Sarkar B; Celik C; Ghosh A; Basu U; Jana M; Jana A; Gencay A; Can Sezgin G; Ildiz N; Dam P; Mandal AK; Ocsoy I
    Phytother Res; 2020 Oct; 34(10):2425-2428. PubMed ID: 32488956
    [No Abstract]   [Full Text] [Related]  

  • 100. Antiviral activity and safety profile of silibinin in HCV patients with advanced fibrosis after liver transplantation: a randomized clinical trial.
    Rendina M; D'Amato M; Castellaneta A; Castellaneta NM; Brambilla N; Giacovelli G; Rovati L; Rizzi SF; Zappimbulso M; Bringiotti RS; Di Leo A
    Transpl Int; 2014 Jul; 27(7):696-704. PubMed ID: 24673819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.